Risk-sharing agreement based on health outcomes for the treatment of moderate severe psoriasis with certolizumab pegol

Objective: To provide evidence of the effectiveness of certolizumab pegol (CZP) in real clinical practice in adult patients with moderate-to-severe plaque psoriasis (PsO) in the context of a risk-sharing agreement (RSA). Methods: Retrospective observational study based on variables collected in the...

ver descrição completa

Detalhes bibliográficos
Autores: Navarro Ruiz A, Toledo Alberola F, Aceituno S
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Recursos:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p15738
Acesso em linha:https://fisabio.portalinvestigacion.com/publicaciones/15738
Access Level:acceso abierto
Palavra-chave:Risk-sharing agreement
Psoriasis
Health outcomes
Effectiveness
Certolizumab pegol
id ES_2ac7dbb514ed501d2c70f4f08a0cd791
oai_identifier_str oai:fisabio.fundanetsuite.com:p15738
network_acronym_str ES
network_name_str España
repository_id_str
spelling Risk-sharing agreement based on health outcomes for the treatment of moderate severe psoriasis with certolizumab pegolNavarro Ruiz AToledo Alberola FAceituno SRisk-sharing agreementPsoriasisHealth outcomesEffectivenessCertolizumab pegolObjective: To provide evidence of the effectiveness of certolizumab pegol (CZP) in real clinical practice in adult patients with moderate-to-severe plaque psoriasis (PsO) in the context of a risk-sharing agreement (RSA). Methods: Retrospective observational study based on variables collected in the RSA for treatment with CZP of adult patients with moderate-severe plaque PsO. Ten Spanish hospitals where the RSA was implemented participated. The percentage of patients who achieved the target clinical response of the RSA at the follow-up visit (week 16) was evaluated: absolute Psoriasis Area and Severity Index (PASI) value <= 3 for biologic na & iuml;ve population, and <= 5 in case of previous failure to a single biologic drug. In addition, the improvement in the scores of other scales included in the study was analyzed: Body Surface Area (BSA), Dermatology Life Quality Index (DLQI), Physician's Global Assessment (PGA), and Nail Psoriasis Severity Index (NAPSI). A descriptive analysis was performed for the total population and by patient subgroups (naive vs. non-naive to biologic, male vs. female, and with vs. without discontinuation). Results: Sixty-six patients were included, 12 men and 54 women. 90.9% achieved the target clinical response, with a mean reduction of 8 (-78.4%) absolute PASI points. Improvement was observed in BSA, PGA, NAPSI and DLQI, with a reduction of 11.3 (-80.6%), 1.9 (-65.5%), 3.3 (-30.7%) and 9.0 (-66.4%) absolute value points, respectively. Despite not achieving the therapeutic target set in the RSA in six patients (9%) (the cost of the drug was assumed by the laboratory), only two (3%) discontinued treatment. Conclusion: Our study shows that CZP is effective in real clinical practice in patients with moderate-severe plaque PsO, with an improvement in absolute PASI and DLQI, as well as other scales, both for the total population and in the subgroups analyzed. Nearly 91% of patients reached the therapeutic target fixed in the RSA. Implementing this type of agreement can provide a direct or indirect benefit for all the agents involved in the process, providing valuable information for decision-making. (c) 2023 Sociedad Espa & ntilde;ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa & ntilde;a, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ELSEVIER SCIENCE INC2024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/15738FARMACIA HOSPITALARIAISSN: 11306343ISSNe: 21718695reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p157382026-06-11T12:45:17Z
dc.title.none.fl_str_mv Risk-sharing agreement based on health outcomes for the treatment of moderate severe psoriasis with certolizumab pegol
title Risk-sharing agreement based on health outcomes for the treatment of moderate severe psoriasis with certolizumab pegol
spellingShingle Risk-sharing agreement based on health outcomes for the treatment of moderate severe psoriasis with certolizumab pegol
Navarro Ruiz A
Risk-sharing agreement
Psoriasis
Health outcomes
Effectiveness
Certolizumab pegol
title_short Risk-sharing agreement based on health outcomes for the treatment of moderate severe psoriasis with certolizumab pegol
title_full Risk-sharing agreement based on health outcomes for the treatment of moderate severe psoriasis with certolizumab pegol
title_fullStr Risk-sharing agreement based on health outcomes for the treatment of moderate severe psoriasis with certolizumab pegol
title_full_unstemmed Risk-sharing agreement based on health outcomes for the treatment of moderate severe psoriasis with certolizumab pegol
title_sort Risk-sharing agreement based on health outcomes for the treatment of moderate severe psoriasis with certolizumab pegol
dc.creator.none.fl_str_mv Navarro Ruiz A
Toledo Alberola F
Aceituno S
author Navarro Ruiz A
author_facet Navarro Ruiz A
Toledo Alberola F
Aceituno S
author_role author
author2 Toledo Alberola F
Aceituno S
author2_role author
author
dc.subject.none.fl_str_mv Risk-sharing agreement
Psoriasis
Health outcomes
Effectiveness
Certolizumab pegol
topic Risk-sharing agreement
Psoriasis
Health outcomes
Effectiveness
Certolizumab pegol
description Objective: To provide evidence of the effectiveness of certolizumab pegol (CZP) in real clinical practice in adult patients with moderate-to-severe plaque psoriasis (PsO) in the context of a risk-sharing agreement (RSA). Methods: Retrospective observational study based on variables collected in the RSA for treatment with CZP of adult patients with moderate-severe plaque PsO. Ten Spanish hospitals where the RSA was implemented participated. The percentage of patients who achieved the target clinical response of the RSA at the follow-up visit (week 16) was evaluated: absolute Psoriasis Area and Severity Index (PASI) value <= 3 for biologic na & iuml;ve population, and <= 5 in case of previous failure to a single biologic drug. In addition, the improvement in the scores of other scales included in the study was analyzed: Body Surface Area (BSA), Dermatology Life Quality Index (DLQI), Physician's Global Assessment (PGA), and Nail Psoriasis Severity Index (NAPSI). A descriptive analysis was performed for the total population and by patient subgroups (naive vs. non-naive to biologic, male vs. female, and with vs. without discontinuation). Results: Sixty-six patients were included, 12 men and 54 women. 90.9% achieved the target clinical response, with a mean reduction of 8 (-78.4%) absolute PASI points. Improvement was observed in BSA, PGA, NAPSI and DLQI, with a reduction of 11.3 (-80.6%), 1.9 (-65.5%), 3.3 (-30.7%) and 9.0 (-66.4%) absolute value points, respectively. Despite not achieving the therapeutic target set in the RSA in six patients (9%) (the cost of the drug was assumed by the laboratory), only two (3%) discontinued treatment. Conclusion: Our study shows that CZP is effective in real clinical practice in patients with moderate-severe plaque PsO, with an improvement in absolute PASI and DLQI, as well as other scales, both for the total population and in the subgroups analyzed. Nearly 91% of patients reached the therapeutic target fixed in the RSA. Implementing this type of agreement can provide a direct or indirect benefit for all the agents involved in the process, providing valuable information for decision-making. (c) 2023 Sociedad Espa & ntilde;ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa & ntilde;a, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
publishDate 2024
dc.date.none.fl_str_mv 2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/15738
url https://fisabio.portalinvestigacion.com/publicaciones/15738
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv ELSEVIER SCIENCE INC
publisher.none.fl_str_mv ELSEVIER SCIENCE INC
dc.source.none.fl_str_mv FARMACIA HOSPITALARIA
ISSN: 11306343
ISSNe: 21718695
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869405094100860928
score 15,812429

Registos relacionados